Regulation of cell survival by resveratrol involves inhibition of NFκB-regulated gene expression in prostate cancer cells

Prostate

Volumn 69, Issue 10, 2009, Pages 1045-1054

  Benitez, Dixan A ^a,c   Hermoso, Marcela A ^a   Pozo Guisado, Eulalia ^b   Fernández Salguero, Pedro M ^b   Castellón, Enrique A ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF EXTREMADURA   (Spain)

^c División Científico Técnica   (Spain)

Author keywords

LNCaP cells; NF B; PC 3 cells; Prostate cancer; Resveratrol

Indexed keywords

EPIDERMAL GROWTH FACTOR; I KAPPA B ALPHA; LUCIFERASE; RESVERATROL; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN SUBUNIT; STILBENE DERIVATIVE;

ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DNA BINDING; DNA SEQUENCE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL FRACTIONATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION; STILBENES; SUBCELLULAR FRACTIONS; TRANSCRIPTION FACTOR RELA;

EID: 67449123012     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20953     Document Type: Article

References (66)

1. Werny DM, Saraiya M, Chen X, Platz EA. Prostate-specific antigen, sexual behavior, and sexually transmitted infections in US men 40-59 years old, 2001-2004: A cross-sectional study. Infect Agent Cancer 2007;2:19.
2. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-362.
3. Wilding G. The importance of steroid hormones in prostate cancer. Cancer Surv 1992;14:113-130.
4. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: What went wrong? J Urol 2000;164:3-9.
5. Evans BA, Harper ME, Daniells CE, Watts CE, Matenhelia S, Green J, Griffiths K. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 1996;28:162-171. (Pubitemid 26110736)
6. Haapala K, Hyytinen ER, Roiha M, Laurila M, Rantala I, Helin HJ, Koivisto PA. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001;81:1647-1651. (Pubitemid 33144427)
7. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ. Androgen receptor mutations in prostate cancer. Cancer Res 2000;60:944-949. (Pubitemid 30129530)
8. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-406.
9. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-1398.
10. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-285. (Pubitemid 26074615)
11. Khan SA, Rogers MA, Obando JA, Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994;54:993-997. (Pubitemid 2041247)
12. Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG, Gershenson DM. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 2007; 26:404-409. (Pubitemid 47476325)
13. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Metastases of prostate cancer express estrogen receptor-beta. Urology 2004;64:814-820. (Pubitemid 39446081)
14. Clinton SK, Giovannucci E. Diet, nutrition, and prostate cancer. Annu Rev Nutr 1998;18:413-440.
15. Romero-Cagigal I, Ferruelo-Alonso A, Berenguer-Sanchez A. Diet and prostate cancer. Actas Urol Esp 2003;27:399-409.
16. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997;29:95-120.
17. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85:60-67.
18. Ramos S. Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways. Mol Nutr Food Res 2008;52:507-526.
19. Santangelo C, Vari R, Scazzocchio B, Di Benedetto R, Filesi C, Masella R. Polyphenols, intracellular signalling and inflammation. Ann Ist Super Sanita 2007;43:394-405.
20. Biesalski HK. Polyphenols and inflammation: Basic interactions. Curr Opin Clin Nutr Metab Care 2007;10:724-728.
21. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: Progress and promise. Cancer Epidemiol Biomarkers Prev 2007;16:2193-2203. (Pubitemid 351196348)
22. Soobrattee MA, Bahorun T, Aruoma OI. Chemopreventive actions of polyphenolic compounds in cancer. Biofactors 2006;27:19-35. (Pubitemid 44434930)
23. Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: Progress and promise. Antioxid Redox Signal 2008;10:475-510.
24. Stevenson DE, Hurst RD. Polyphenolic phytochemicals - Just antioxidants or muchmore? Cell Mol Life Sci 2007;64:2900-2916.
25. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 2006;72:1439-1452. (Pubitemid 44666744)
26. Sanders TH, McMichael RW Jr, Hendrix KW. Occurrence of resveratrol in edible peanuts. J Agric Food Chem 2000;48:1243-1246.
27. Sobolev VS, Cole RJ. trans-resveratrol content in commercial peanuts and peanut products. J Agric Food Chem 1999;47:1435-1439. (Pubitemid 29217135)
28. Fremont L. Biological effects of resveratrol. Life Sci 2000;66:663-673.
29. Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B, Fernandez-Salguero PM. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: Cell-specific alteration of the cell cycle. Biochem Pharmacol 2002;64:1375-1386. (Pubitemid 35248254)
30. Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, Centeno F, Alvarez-Barrientos A, Fernandez-Salguero PM. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 2005;115:74-84. (Pubitemid 40559670)
31. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 2007;28:282-293. (Pubitemid 46423911)
32. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 2000;60:3175-3182. (Pubitemid 30407914)
33. Benitez DA, Pozo-Guisado E, Clementi M, Castellon E, Fernandez-Salguero PM. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: Modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 2007;96: 1595-1604. (Pubitemid 46762955)
34. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, Aggarwal BB. Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol 2002;169:6490-6497. (Pubitemid 36903500)
35. Muller CW, Rey FA, Sodeoka M, Verdine GL, Harrison SC. Structure of the NF-kappa B p50 homodimer bound to DNA. Nature 1995;373:311-317.
36. Sedgwick JD, Riminton DS, Cyster JG, Korner H. Tumor necrosis factor: A master-regulator of leukocyte movement. Immunol Today 2000;21:110-113. (Pubitemid 30122696)
37. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-2224.
38. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. TrendsImmunol 2004;25:280-288. (Pubitemid 38610351)
39. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109 (Suppl.):S81-S96.
40. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20:7597-7609. (Pubitemid 33111860)
41. Sumitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F, Hayakawa M, Nakamura H. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J Urol 1999;161:674-679.
42. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999;18:7389-7394. (Pubitemid 30032121)
43. Chendil D, Ranga RS, Meigooni D, Sathishkumar S,AhmedMM. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004;23:1599-1607. (Pubitemid 38406523)
44. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001;98:10350-10355. (Pubitemid 32803023)
45. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovitch L, Malone WA, Crowell JA, Sigman CC. Chemo-prevention of prostate cancer: Concepts and strategies. Eur Urol 1999;35:342-350. (Pubitemid 29229531)
46. Safe S, Wargovich MJ, Lamartiniere CA, Mukhtar H. Symposium on mechanisms of action of naturally occurring anticarcinogens. Toxicol Sci 1999;52:1-8.
47. Pervaiz S. Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol. Drug Resist Updat 2004;7:333-344. (Pubitemid 40341955)
48. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. J Nutr Biochem 2005;16:449-466. (Pubitemid 41039220)
49. Von Low EC, Perabo FG, Siener R, Muller SC. Review. Facts and fiction of phytotherapy for prostate cancer:Acritical assessment of preclinical and clinical data. In Vivo 2007;21:189-204. (Pubitemid 46534271)
50. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RW. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 2007;67:1641-1653. (Pubitemid 350036950)
51. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-85. (Pubitemid 29418447)
52. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999;401:86-90. (Pubitemid 29418448)
53. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Aggarwal BB. Resveratrol blocks interleukin-1betainduced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003;102:987-995. (Pubitemid 36917794)
54. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000;164:6509-6519. (Pubitemid 30408836)
55. Shukla S, Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: Correlation with down-regulation of NF-kappaB-responsive genes. Clin Cancer Res 2004;10: 3169-3178. (Pubitemid 38619698)
56. Jeong WS, Kim IW, Hu R, Kong AN. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res 2004;21:661-670. (Pubitemid 38457289)
57. Katula KS, McCain JA, Radewicz AT. Relative ability of dietary compounds to modulate nuclear factor-kappaB activity as assessed in a cell-based reporter system. J Med Food 2005;8:269-274. (Pubitemid 41008995)
58. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, Rabson AB. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002;52:183-200. (Pubitemid 34791221)
59. Li Y, Sarkar FH. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002;8:2369-2377. (Pubitemid 34753612)
60. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-310. (Pubitemid 37328783)
61. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002;115:141-151. (Pubitemid 34105537)
62. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 2003;91:417-420. (Pubitemid 36359653)
63. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: An immunohistochemical study. Br J Cancer 2005;93:1019-1023. (Pubitemid 41548396)
64. Haefner B. NF-Kappa B: Arresting a major culprit in cancer. Drug Discov Today 2002;7:653-663.
65. Ko S, Shi L, Kim S, Song CS, Chatterjee B. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Mol Endocrinol 2008;22:273-286. (Pubitemid 351185931)
66. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr, Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 2003;97:1211-1216. (Pubitemid 36237306)